
Hologic ( HOLX ) Down 0.3% Since Last Earnings Report: Can It Rebound?
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TMO's growth, driven by new partnerships and strong end markets, faces challenges from macro pressures and fierce competition.
Thermo Fisher Scientific TMO has outperformed the market over the past 20 years by 6.79% on an annualized basis producing an average annual return of 15.43%. Currently, Thermo Fisher Scientific has a market capitalization of $185.14 billion.
Austin, TX, USA, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled "Chemical Reagents Market Size, Trends and Insights By Product Type ( Solvents, Acids & Bases, Oxidizing & Reducing Agents, Buffers & Standards, Catalysts ) , By Application ( ...
Lewes, Delaware, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- The Global Biobanking Market Size is projected to grow at a CAGR of 9.89% from 2024 to 2031, according to a new report published by Verified Market Research®.
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Austin, TX, USA, Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled "Induced Pluripotent Stem Cells Production Market Size, Trends and Insights By Process ( Manual iPSC Production, Automated iPSC Production ) , By Workflow ( Cell Culture, Cell ...
Boston, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, the "Genome Editing: Technologies and Global Markets" is projected to grow from $10.8 billion in 2025 to $23.7 billion by the end of 2030, at a compound annual growth rate ( CAGR ) of 16.9% during the ...
According to one pundit, the company has a hard-to-beat mix of quality products and services.
Thermo Fisher stock is projected to reach $598 by 2026, offering 22% upside. Shares have fallen 27% since 2021, trailing the S&P's 30% gain, but the long-term outlook is strong. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
IBM, Goldman Sachs and Thermo Fisher stand out in Zacks research with AI growth, strong banking results and new product launches.
AUSTIN, Texas, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Astrotech Corporation ( Nasdaq: ASTC ) ( the "Company" or "Astrotech" ) , today announced that it has appointed Nihanth Badugu as Chief Operating Officer ( "COO" ) of the Company. Mr. Badugu's appointment is effective as of August 13, 2025.
Investors with a lot of money to spend have taken a bearish stance on Thermo Fisher Scientific TMO. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
CBRE, Acadian, and Fastenal highlight Zacks' market-beating picks as portfolios outpace broader indexes with strong 2025 gains.
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
On CNBC's "Halftime Report Final Trades," Ritholtz Wealth Management CEO Joshua Brown named Toast, Inc. TOST following the release of quarterly results. On Aug. 5, the company reported quarterly earnings of 13 cents per share. It exceeded the analyst consensus estimate of 11 cents per share.
SEATTLE, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- ( NASDAQ: BNZI ) ( "Banzai" or the "Company" ) , a leading marketing technology company that provides essential marketing and sales solutions, today announced the appointment of Matt McCurdy as Vice President of Sales to lead strategic growth and ...
Austin, TX, USA, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled "AI in Synthetic Biology Market Size, Trends and Insights By Technology ( Gene Synthesis, Genome Editing, Synthetic Biology Tools, Bioinformatics ) , By Application ( Healthcare ...
Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings ...
Engine estimates Avantor's strategic value at $17-$19 per share, a 50% premium. LSS margins trail Thermo Fisher's comparable division by 450 basis points. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → Avantor Inc.
Lewes, Delaware, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The Global Veterinary Diagnostics Market Size is projected to grow at a CAGR of 6.59% from 2024 to 2031, according to a new report published by Verified Market Research®.
Burlingame, CA, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- The global Baculovirus Expression System Market is estimated to be valued at USD 436.0 Mn in 2025 and is expected to reach USD 781.8 Mn in 2032, exhibiting a compound annual growth rate ( CAGR ) of 8.7% from 2025 to 2032.
Boston, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, the "Global Markets for Allergy Diagnostics and Treatments" is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030, at a compound annual growth rate ( CAGR ) of 7.3% from ...
SEATTLE, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- ( NASDAQ: BNZI ) ( "Banzai" or the "Company" ) , a leading marketing technology company that provides essential marketing and sales solutions, will hold a conference call on Thursday, August 14, 2025, at 4:30 p.m.
SEATTLE, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Banzai International, Inc. BNZI ( "Banzai" or the "Company" ) , a leading marketing technology company that provides essential marketing and sales solutions, will hold a conference call on Thursday, August 14, 2025, at 4:30 p.m.
FDA-cleared PreClara™ Ratio ( sFlt-1/PlGF ) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes
FDA-cleared PreClara™ Ratio ( sFlt-1/PlGF ) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes ...
JENA, Germany, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- InflaRx N.V. ( Nasdaq: IFRX ) , a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended June 30, 2025, and provided a business ...
Seer ( NASDAQ:SEER ) , a life sciences technology firm specializing in advanced proteomics, released its second quarter results for fiscal 2025 on August 6, 2025. Seer reported GAAP revenue of $4.1 million, topping consensus estimates of $3.75 million by $0.35 million and marking a 32% increase ...
Image source: The Motley Fool.Wednesday, Aug. 6, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
Thermo Fisher Scientific TMO has outperformed the market over the past 10 years by 1.59% on an annualized basis producing an average annual return of 13.23%. Currently, Thermo Fisher Scientific has a market capitalization of $175.96 billion.
DURHAM, N.C., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Fortrea ( Nasdaq: FTRE ) , a leading global contract research organization ( CRO ) , today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue ...
Oracle, Credo Tech, and Palantir shine in volatile markets, leading Zacks portfolios with standout gains and upgraded outlooks.
CI's Q2 earnings benefit from strong Evernorth Health Services unit, offsetting customer losses and rising costs. It continues to expect 2025 adjusted EPS at a minimum of $29.60.
Thermo Fisher Scientific TMO has outperformed the market over the past 10 years by 1.45% on an annualized basis producing an average annual return of 13.22%. Currently, Thermo Fisher Scientific has a market capitalization of $177.93 billion.
Thermo Fisher Scientific ( NYSE:TMO ) , a leading provider of scientific instrumentation, reagents and consumables, and specialty diagnostics, reported its second quarter results for fiscal 2025 on July 23, 2025. The company delivered higher revenue and non-GAAP earnings per share than Wall ...
Deep-pocketed investors have adopted a bearish approach towards Thermo Fisher Scientific TMO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Medpace surged over 137% after crushing Q2 earnings estimates. Strong earnings and raised guidance drove sharp gains in pharma and tech names. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. These ten large-cap stocks were top performers last week.
Thermo Fisher Scientific TMO has outperformed the market over the past 20 years by 6.48% on an annualized basis producing an average annual return of 14.98%. Currently, Thermo Fisher Scientific has a market capitalization of $181.46 billion.
Austin, TX, USA, July 25, 2025 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled "CRISPR Gene Editing Market Size, Trends and Insights By Product ( Kits and Reagents, Services ) , By Gene Editing Modality ( Ex-Vivo Editing, In-Vivo Editing ) , By Technology ...
Thermo Fisher Scientific ( NYSE:TMO ) , a leader in life sciences tools and diagnostics, reported its second quarter 2025 results on July 23, 2025. The company outpaced expectations on both revenue and non-GAAP EPS, delivering $10.85 billion in revenue and $5.36 in non-GAAP EPS versus analyst ...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 350 points on Wednesday. The Dow traded up 0.82% to 44,869.16 while the NASDAQ rose 0.16% to 20,925.86. The S&P 500 also rose, gaining, 0.44% to 6,337.46. Industrials shares jumped by 1.1% on Wednesday.
Thermo Fisher Q2 earnings of $5.36/share beat estimates of $5.23; revenue rose 3% YoY to $10.86 billion. 2025 revenue guidance raised to $43.6 billion-$44.2 billion; EPS forecast increased to $22.22-$22.84.
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc. GEV rose sharply during Wednesday's session after the company posted better-than-expected second-quarter 2025 earnings and raised its full-year guidance.
TMO tops Q2 estimates as new product launches and solid segment growth fuel revenue gains despite margin pressure.